- Todos > Medicine Information and Evidence for Policy > Medicines Policy
- Todos > Medicine Information and Evidence for Policy > Monitoring and Evaluation
- Palabras clave > access to medicines
- Palabras clave > ATM-related practices
- Palabras clave > indicator-based approach
- Palabras clave > methodology
- Palabras clave > pharmaceutical company ranking
- Palabras clave > pharmaceutical industry
- Palabras clave > pharmaceutical industry - performance
- Palabras clave > pharmaceutical industry - role
- Palabras clave > pharmaceutical industry social responsibility
(2017; 80 pages)
The Access to Medicine Index analyses 20 of the largest research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. The Index ranks these companies according to their efforts to improve access to medicine in these countries. It identifies best practices, highlights where progress is being made, and uncovers where critical action is still required. In this way, the Index provides both a guide and an incentive for pharmaceutical companies working to do more for people who lack access to medicine.
In 2016, the Access to Medicine Index reported that pharmaceutical companies are getting more sophisticated in how they get essential products to poor people. However, good practice was found to be limited to a narrow range of products and countries, and many opportunities to expand good practice are yet to be acted upon.
The Index methodology is updated every two years to take account of new developments and emerging challenges in access to medicine. Each methodology review is informed by a wide-ranging multi-stakeholder dialogue coordinated by the Access to Medicine Foundation. For more than ten years, the Foundation has built stakeholder consensus on what we can expect from pharmaceutical companies.